Iambic Therapeutics Inc. (IAM)
NASDAQ: IAMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IAM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $621.42M
- EPS (TTM)
- -$2.69
- Dividend yield
- None
- 52-week range
- 9.60 – 25.00
- Day range
- 12.77 – 14.00
- Volume / Avg
- 281.91K / 714.92K
- Beta
- —
- Shares outstanding
- 47.40M
52-week range
IAM stock today
Iambic Therapeutics (IAM) closed at $13.11 on Nov 20, down 8.06% (-$1.15), versus the S&P 500's 3.70% decline. Trading was light, with 281.91K shares changing hands, about 39% of the average daily volume. Shares are 47.6% below their 52-week high of $25.00, set on Oct 16, 2026 and 36.6% above the 52-week low of $9.60, in the middle of the past year's range.
Iambic Therapeutics has posted a net loss over the last twelve months (EPS of -$2.69), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Iambic Therapeutics
Company profileIambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop small molecule therapeutics.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Thomas Miller Ph.D.
- Headquarters
- San Diego, CA
- Employees
- 171
- IPO year
- 2026
- Website
- iambic.ai
Analyst forecast
ForecastConsensus (4 analysts)
strong_buy
Avg. price target
$27.25+107.86%
- Strong buy 1
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-6.23 vs $-0.33
- Surprise
- -1787.88%
IAM news
All IAM news- Iambic Presents Preclinical Data for CDK2/4 Inhibitor IAM-C1 and Brain-Penetrant KIF18A Inhibitor IAM217 at 2026 EORTC-NCI-AACR SymposiumGlobeNewswire
- Iambic Therapeutics, Inc. GAAP EPS of -$8.52 misses by $7.75, revenue of $11.4M beats by $3.11MSeeking Alpha
- Iambic Provides Business Updates and Third Quarter 2026 Financial ResultsGlobeNewswire
- Iambic Shares Rise Ahead Of AI Drug Discovery Panel At Jefferies Healthcare ConferenceNasdaqIAM, BF.A
- Iambic to participate in Jefferies Global Healthcare ConferenceGlobeNewswire
- Tuesday 10/20 Insider Buying Report: IAM, FISNasdaqIAM, FIS
Iambic Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SRZNSurrozen Inc. | 28.46 | -7.21% | $596.40M | vs IAM |
| CGEMCullinan Therapeutics Inc. | 8.89 | -1.98% | $577.15M | vs IAM |
| FDMT4D Molecular Therapeutics Inc. | 10.23 | -4.57% | $576.76M | vs IAM |
| ENTXEntera Bio Ltd. | 3.31 | +0.76% | $575.53M | vs IAM |
| DBVTDBV Technologies S.A. ADR | 9.02 | -4.25% | $566.82M | vs IAM |
| ATTOAttovia Therapeutics Inc. | 15.10 | -3.08% | $690.26M | vs IAM |
| SLDBSolid Biosciences Inc. | 6.25 | -2.95% | $697.57M | vs IAM |
| AURAAura Biosciences Inc. | 6.87 | -1.58% | $714.99M | vs IAM |
Indexes, lists and sector
Iambic Therapeutics stock FAQ
What is Iambic Therapeutics's stock price today?
IAM last traded at $13.11 as of Nov 20, 4:00 PM EST, down 8.06% on the day. Prices are delayed at least 15 minutes.
Who is Iambic Therapeutics's CEO?
Dr. Thomas Miller Ph.D. is the chief executive officer of Iambic Therapeutics Inc., which has about 171 employees.
What is the IAM 52-week high?
The 52-week high for IAM is $25.00 and the 52-week low is $9.60. The stock is currently 47.6% below its high.